Shire-Movetis NV provided funding to Oxford PharmaGenesis™ Ltd fo

Shire-Movetis NV provided funding to Oxford PharmaGenesis™ Ltd for support in writing and editing this manuscript. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in Drugs in R&D was made by the authors independently. The authors confirm that the data presented provide an accurate representation of the study results. Author Contributions Vera Van de Velde and Lieve Vandeplassche were involved in the conception of the study and interpretation of the data. Mieke Hoppenbrouwers was involved in conception, GSK2126458 analysis, and interpretation. Mark

Boterman was involved in laboratory testing and analysis of the data. Jannie Ausma was Selumetinib clinical trial responsible for coordinating the study and was also involved in the conception, analysis, and interpretation of the data.

All authors were involved throughout the development of the manuscript. Conflict of Interest Disclosures Vera Van de Velde has received consultancy fees from Shire-Movetis NV. Mark Boterman’s institution (Analytisch Biochemisch Laboratorium BV) received a grant from Shire-Movetis NV for analysis of the study samples. Lieve Vandeplassche, Mieke Hoppenbrouwers, and Jannie Ausma are employees of Shire-Movetis NV and hold stock/stock options in Shire. The authors have no other conflicts of interest that are directly relevant CP673451 manufacturer to the content of this article. Open AccessThis article Bumetanide is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial

use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. European Medicines Agency. Resolor (prucalopride): summary of product characteristics. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​001012/​WC500053998.​pdf. Accessed 26 March 2012. 2. Frampton JE. Prucalopride. Drugs. 2009;69(17):2463–76.PubMedCrossRef 3. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–54.PubMedCrossRef 4. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation: a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29(3):315–28.PubMedCrossRef 5. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357–65.PubMedCrossRef 6. Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008;28(7):917–30.PubMed 7.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>